Willem W Overwijk

Willem W Overwijk

UNVERIFIED PROFILE

Are you Willem W Overwijk?   Register this Author

Register author
Willem W Overwijk

Willem W Overwijk

Publications by authors named "Willem W Overwijk"

Are you Willem W Overwijk?   Register this Author

68Publications

2297Reads

45Profile Views

Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer.

ACS Nano 2018 10 21;12(10):9881-9893. Epub 2018 Sep 21.

Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy , University of Houston , Houston , Texas 77030 , United States.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/10.1021/acsnano.8b02481
Publisher Site
http://dx.doi.org/10.1021/acsnano.8b02481DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245606PMC
October 2018

The immune system in cancer metastasis: friend or foe?

J Immunother Cancer 2017 10 17;5(1):79. Epub 2017 Oct 17.

Departments of Melanoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-017-0283-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644253PMC
October 2017

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.

Neuro Oncol 2017 Aug;19(8):1047-1057

Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas; Caris Life Sciences, Phoenix, Arizona; Departments of Biostatistics, Neuro-Pathology, Neuro-Oncology, Pediatrics, and Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/nox026DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570198PMC
August 2017

Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant.

Curr Opin Immunol 2017 Aug 12;47:103-109. Epub 2017 Aug 12.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coi.2017.07.015DOI Listing
August 2017

Immune cell profiling in cancer: molecular approaches to cell-specific identification.

NPJ Precis Oncol 2017 15;1(1):26. Epub 2017 Aug 15.

1Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41698-017-0031-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871917PMC
August 2017

The making of a killer (T cell).

Oncotarget 2017 Feb;8(7):10767-10768

Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.15229DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355215PMC
February 2017

Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma.

J Immunother 2017 01;40(1):11-20

Departments of *Stem Cell Transplantation and Cellular Therapy †Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China ‡Melanoma Medical Oncology §Cancer Systems Imaging ∥Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0000000000000145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138115PMC
January 2017

Temporally Programmed CD8α DC Activation Enhances Combination Cancer Immunotherapy.

Cell Rep 2016 12;17(10):2503-2511

Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2016.11.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5204262PMC
December 2016

IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation.

Cancer Immunol Res 2016 11 3;4(11):983-994. Epub 2016 Oct 3.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0195DOI Listing
November 2016

Adjuvants for peptide-based cancer vaccines.

J Immunother Cancer 2016 20;4:56. Epub 2016 Sep 20.

Department of Melanoma Medical Oncology, University of Texas - MD Anderson Cancer Center, South Campus Research Building 1, 1515 Holcombe Blvd, Houston, TX 77030 USA ; Immunology program - University of Texas - Graduate School of Biomedical Sciences at Houston, 6767 Bertner Ave, Houston, TX 77030 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0160-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028954PMC
September 2016

The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications.

Int Rev Immunol 2016 07 26;35(4):325-339. Epub 2014 Sep 26.

a Department of Pediatrics-Research , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/08830185.2014.956360DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5257246PMC
July 2016

Soluble interleukin-15 complexes are generated in vivo by type I interferon dependent and independent pathways.

PLoS One 2015 10;10(3):e0120274. Epub 2015 Mar 10.

Departments of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America; Immunology Graduate Program, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0120274PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354909PMC
January 2016

Intratumoral immunotherapy for melanoma.

Cancer Immunol Immunother 2015 Jul 7;64(7):911-21. Epub 2015 Jun 7.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 7455 Fannin St., Unit 0904, Houston, TX, 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-015-1727-zDOI Listing
July 2015

Human CD4(+) T cells spontaneously detect somatic mutations in cancer cells.

Nat Med 2015 Jan;21(1):12-4

Department of Melanoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.3783DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055476PMC
January 2015

Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.

J Immunol 2014 Nov 24;193(9):4722-31. Epub 2014 Sep 24.

Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030; University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX 77030;

View Article

Download full-text PDF

Source
http://www.jimmunol.org/lookup/doi/10.4049/jimmunol.1401160
Publisher Site
http://dx.doi.org/10.4049/jimmunol.1401160DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201984PMC
November 2014

Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination.

Int J Biochem Cell Biol 2014 Aug 2;53:46-50. Epub 2014 May 2.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The University of Texas Graduate School of Biomedical Sciences at Houston, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biocel.2014.04.019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4111967PMC
August 2014

Characterization of the inflammatory microenvironment and identification of potential therapeutic targets in wilms tumors.

Transl Oncol 2014 Aug 23;7(4):484-92. Epub 2014 Jun 23.

Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Graduate Program in Genes and Development and Graduate Program in Human Molecular Genetics, The University of Texas Graduate School of Biomedical Sciences, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tranon.2014.05.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202801PMC
August 2014

Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors.

J Immunother Cancer 2013 29;1:11. Epub 2013 Jul 29.

Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA ; NIH Center for Regenerative Medicine, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/2051-1426-1-11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019909PMC
June 2014

Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice.

Nat Med 2014 Jun 25;20(6):676-81. Epub 2014 May 25.

1] Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. [2] Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. [3] The University of Texas Graduate School of Biomedical Sciences, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.3560DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048321PMC
June 2014

Harnessing the power of the immune system to target cancer.

Annu Rev Med 2013 22;64:71-90. Epub 2012 Oct 22.

Department of Melanoma Medical Oncology, The Center for Cancer Immunology Research, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://www.annualreviews.org/doi/10.1146/annurev-med-112311-
Publisher Site
http://dx.doi.org/10.1146/annurev-med-112311-083918DOI Listing
July 2013

Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard.

Oncoimmunology 2013 Jul 30;2(7):e24743. Epub 2013 Apr 30.

Department of Melanoma Medical Oncology; The University of Texas MD Anderson Cancer Center; Houston, TX USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/onci.24743DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782014PMC
July 2013

Differential expression of the G-protein-coupled formyl Peptide receptor in melanoma associates with aggressive phenotype.

Am J Dermatopathol 2013 Apr;35(2):184-90

Department of Pathology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0b013e31825b2506DOI Listing
April 2013

Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40.

Blood 2012 Nov 30;120(23):4533-43. Epub 2012 Aug 30.

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2012-02-407163DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512233PMC
November 2012

PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines.

Cancer Res 2012 Oct 20;72(20):5209-18. Epub 2012 Aug 20.

Department of Melanoma Medical Oncology, The Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-12-1187DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3476734PMC
October 2012

Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo.

J Immunother 2012 Apr;35(3):276-82

Department of Melanoma Medical Oncology, The Center for Cancer Immunology Research, University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0b013e31824e7f43DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3860320PMC
April 2012

Conference scene: immune effector mechanisms in tumor immunity.

Immunotherapy 2012 Feb;4(2):141-3

Departments of Otolaryngology, Immunology, Oncological Sciences & Dermatology, Mount Sinai School of Medicine, New York, NY 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt.11.177DOI Listing
February 2012

Antitumor activity mediated by CpG: the route of administration is critical.

J Immunother 2011 Apr;34(3):279-88

Department of Melanoma Medical Oncology, The Center for Cancer Immunology Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0b013e31820d2a05DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119202PMC
April 2011

Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses.

Clin Cancer Res 2010 Nov 1;16(22):5458-68. Epub 2010 Oct 1.

Departments of Melanoma Medical Oncology and Experimental Diagnostic Imaging, The Center for Cancer Immunology Research, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-10-0712DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3476703PMC
November 2010

Differential mechanisms of memory CD8 T cell maintenance by individual myeloid cell types.

J Leukoc Biol 2010 Jul 30;88(1):69-78. Epub 2010 Mar 30.

Department of Immunology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1189/jlb.1209816DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2892527PMC
July 2010

Functions of γC cytokines in immune homeostasis: current and potential clinical applications.

Clin Immunol 2009 Aug 9;132(2):153-65. Epub 2009 May 9.

Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clim.2009.03.512DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761713PMC
August 2009

Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy.

Vaccine 2009 May 5;27(25-26):3484-8. Epub 2009 Feb 5.

Department of Melanoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77054, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2009.01.047DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772602PMC
May 2009

Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice.

J Clin Invest 2008 Mar;118(3):1165-75

Department of Melanoma Medical Oncology, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI33583DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2230660PMC
March 2008

IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells.

Int Immunol 2007 Oct;19(10):1213-21

Department of Melanoma Medical Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/intimm/dxm093DOI Listing
October 2007

Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms.

Clin Cancer Res 2006 Aug;12(16):4794-803

Department of Melanoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-0944DOI Listing
August 2006

Immunosuppression in melanoma immunotherapy: potential opportunities for intervention.

Clin Cancer Res 2006 Apr;12(7 Pt 2):2359s-2365s

Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-2537DOI Listing
April 2006

Breaking tolerance in cancer immunotherapy: time to ACT.

Curr Opin Immunol 2005 Apr;17(2):187-94

Department of Melanoma Medical Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 904, Houston, Texas 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coi.2005.01.011DOI Listing
April 2005